Navigation Links
Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients With Advanced Breast Cancer in Phase 2 Study
Date:9/23/2009

BERLIN, Sept. 23 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the full results from their first collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trial showing that Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic agent, capecitabine, significantly extended progression-free survival in patients with advanced breast cancer. The data were presented at the joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress in Berlin.

Jose Baselga, M.D., chairman and professor of medicine at Vall d'Hebron Institute of Oncology in Barcelona, scientific chairman of SOLTI and the principal investigator of this study, reported that patients receiving Nexavar plus capecitabine had a 74 percent improvement in the time they lived without their disease progressing compared to those who received the chemotherapy alone. The difference in median progression-free survival of Nexavar plus capecitabine versus capecitabine plus placebo was statistically significant, 6.4 months vs. 4.1 months (HR=.576, p=0.0006).

"Onyx and Bayer have built a strong foundation with Nexavar in treating unresectable liver cancer and advanced kidney cancer - both disease areas with a previously unmet treatment need," said Todd Yancey, M.D., vice president of clinical development at Onyx. "These new results signify another step in understanding the potential role of Nexavar in breast cancer."

The study evaluated Nexavar in combination with the oral chemotherapeutic, capecitabine, in patients with locally advanced or metastatic HER-2 negative breast cancer. Overall, treatment with Nexavar plus capecitab
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress
2. Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer
3. Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
4. Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer
5. Nexavar Approved in Japan for the Treatment of Advanced Liver Cancer
6. New Analyses Confirm Nexavars Efficacy and Safety in Multiple Patient Subsets With Liver Cancer
7. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar; Previously Announced Fourth Quarter and Full Year 2007 Financial Results Teleconference Rescheduled
8. More Sleep & Less Sex - A Losing Combination
9. Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
10. Diabetes Drug Kills Cancer Stem Cells in Combination Treatment in Mice
11. Mega-Catch™ 3000 Combination Lure Attracts Asian Tiger Mosquitoes (Aedes Albopictus)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... York (PRWEB) October 25, 2014 ... lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) filed against Boston ... in U.S. District Court, Southern District of West ... Judgment on Punitive Damages in a group of ... a ruling issued on October 21st, U.S. District ...
(Date:10/25/2014)... 2014 Limbkeepers® announced today that they ... with Ed Begley Jr, airing 1st QTR 2015 via ... this episode, Innovations will focus on Limbkeepers® non compression ... thinning skin on arms, hands, and legs from abrasion, ... versatile products, which help reduce injuries, allow for continued ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. 24, 2014 ... -- herpes simplex -- might increase the risk of Alzheimer,s ... being a carrier of certain antibodies to the virus can ... "The identification of a treatable cause [herpes simplex] of ... researcher Dr. Hugo Lovheim, an associate professor in the department ...
(Date:10/25/2014)... FRIDAY, Oct. 24, 2014 (HealthDay News) -- Researchers ... say their findings are cause for concern. ... that are raised for human consumption contribute to ... health, according to background information from the study. ... germs sicken about 2 million people and kill ...
(Date:10/25/2014)... Current osteoporosis screening guidelines and tools fail to ... osteoporosis-related fractures, a new study says. "If ... that help us accurately predict who will suffer ... these at-risk people for preventive measures," study author ... division of general internal medicine and health services ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Upcoming Episode of Innovations with Ed Begley, Jr. to Feature Limbkeepers® 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2
... Oct. 10 The Johns Hopkins University School,of ... Adjuvant Breast Cancer Strategies: From Biomarkers to Treatment,Selection," ... latest advances in,breast cancer treatment., In recent ... have,led to chemotherapeutic and biologic treatment combinations that ...
... Course for,Non-Dermatologists about Detection and Management of Melanoma, ... the Royal Sonesta Hotel Boston,Cambridge, MA, CONCORD, ... England and the Boston University School of Medicine ... course to update non-dermatologists on the detection and ...
... Nature,s Way Holding Company, a,subsidiary of ... producer of clinically proven phytomedicines, has reached,agreement ... Therapy with North,Castle Partners, LLC, the controlling ... to other shareholders delivering their signatures and,provides ...
... 38 studies found painkillers showed protective effect , , THURSDAY, ... are associated with a reduced risk for breast cancer, ... an invitation for all women to start popping the ... that to happen here, for people to jump on ...
... care, deliver higher, levels of documentation accuracy, and increase staff ... ... PITTSBURGH, Oct. 9 Vocollect Healthcare Systems, Inc.,announces that Community ... care as part of its,strategic initiative to deliver the utmost ...
... 9 ATS Medical, Inc.,(Nasdaq: ATSI ), ... today that it will participate at the Second,Annual ... Astoria,in New York. Michael Dale, President and CEO ... Time on Monday, October 13, 2008., (Logo: ...
Cached Medicine News:Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Paul Sullivan's Legacy: An Early Warning Program for Detecting Melanoma Before It's Too Late 2Health News:Schwabe, World Leader in Herbal Manufacturing Will Acquire Enzymatic Therapy Through Nature's Way Holding, Inc. 2Health News:Schwabe, World Leader in Herbal Manufacturing Will Acquire Enzymatic Therapy Through Nature's Way Holding, Inc. 3Health News:NSAIDs Might Lower Breast Cancer Risk 2Health News:NSAIDs Might Lower Breast Cancer Risk 3Health News:Community Eldercare Services LLC Deploys Voice-Assisted Care to Revolutionize Care Across Its 20-Facility Enterprise 2Health News:Community Eldercare Services LLC Deploys Voice-Assisted Care to Revolutionize Care Across Its 20-Facility Enterprise 3Health News:ATS Medical to Participate at the Natixis Bleichroeder Second Annual Hidden Gems Conference 2
(Date:10/25/2014)... Calif. , Oct. 24, 2014  America,s ... over friendly robotic competition at the  Medical Design ... on October 29-30 th at the ... will highlight local student built robots from the ... (FIRST) competition.  FIRST students and mentors will offer ...
(Date:10/25/2014)... 24, 2014  The National Association of Drug ... achieved by Kentucky,s real-time, ... The National Precursor Log Exchange (NPLEx) system automatically ... sale and helps flag meth offenders for law ... up NPLEx "watch lists" that notify them via ...
(Date:10/25/2014)... CUPERTINO, Calif. , Oct. 24, 2014 ... ) third quarter 2014 financial results press release, you ... will be broadcast live over the internet on Monday, ... pm Pacific Time). A live audio webcast ... homepage at http://www.durect.com and clicking "Investor Relations."  ...
Breaking Medicine Technology:Local robotics teams compete - a "FIRST" at next week's MD&M Minneapolis- October 29-30th at the Minneapolis Convention Center 2Local robotics teams compete - a "FIRST" at next week's MD&M Minneapolis- October 29-30th at the Minneapolis Convention Center 3Kentucky's NPLEx Technology Making Significant Progress 2DURECT Corporation Invites You to Join its Third Quarter 2014 Earnings Conference Call 2
... the risk of cardiovascular hospitalization or death by 24 ... Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and ... that the ATHENA trial was published in the New ... (dronedarone), in addition to standard therapy, significantly reduced the ...
... a study published in The American Journal of ... Clinic psychiatrist Mark Frye, M.D., attempted to identify what ... to experience treatment-emergent mania (TEM).Bipolar disorder, also known as ... mood instability that can be serious and disabling. The ...
Cached Medicine Technology:New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation 2New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation 3New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation 4New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation 5New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation 6Study Suggests New Treatment Approach May be Needed for Management of Depression in Some People With Bipolar Disorder 2Study Suggests New Treatment Approach May be Needed for Management of Depression in Some People With Bipolar Disorder 3
... watt halogen light source with ... ,SOLOS Endoscopy shares your commitment ... the highest quality care available ... development of advanced surgical instruments ...
Linvatecs single CCD camera heads offer high resolution with the convenience of programmable buttons for sterile field control of the printer and VCR. Available in "V and "C mount in NTSC and PAL....
... camera system offers the latest technology ... controller. Equipped with many of the ... expensive camera controllers, including edge enhancement, ... The controller is compatible and interchangeable ...
... Camera Systems provide the advanced functionality ... need for advanced training. Programmable, easy ... the flexibility needed to accommodate the ... Compatible with both autoclavable and non-autoclavable ...
Medicine Products: